M. Capra Et Al. , "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis," HAEMATOLOGICA , vol.107, no.6, pp.1397-1409, 2022
Capra, M. Et Al. 2022. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. HAEMATOLOGICA , vol.107, no.6 , 1397-1409.
Capra, M., Martin, T., Moreau, P., Baker, R., Pour, L., Min, C., ... Leleu, X.(2022). Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. HAEMATOLOGICA , vol.107, no.6, 1397-1409.
Capra, Marcelo Et Al. "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis," HAEMATOLOGICA , vol.107, no.6, 1397-1409, 2022
Capra, Marcelo Et Al. "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis." HAEMATOLOGICA , vol.107, no.6, pp.1397-1409, 2022
Capra, M. Et Al. (2022) . "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis." HAEMATOLOGICA , vol.107, no.6, pp.1397-1409.
@article{article, author={Marcelo Capra Et Al. }, title={Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis}, journal={HAEMATOLOGICA}, year=2022, pages={1397-1409} }